CRP and amyotrophic lateral sclerosis: In the tocilizumab (Actemra®) clinical trial in ALS “clinicaltrials.gov number NCT02469896 (accessed on 8 January 2025)”, an unexpected (not a predefined study outcome biomarker), but nonetheless interesting, result was that the reduction in CSF C-reactive protein (CRP) occurred only in the CSF of treated ALS patients with at least one Il6R Ala358 allele [8].